ARTICLE | Finance

venBio Selects

venBio Select Fund targets public biotech M&A and partnership candidates

October 11, 2010 7:00 AM UTC

The venBio Select Fund was launched on July 1 and already boasts a nice three-month return due to the proposed takeout of ZymoGenetics Inc. (NASDAQ:ZGEN) by Bristol-Myers Squibb Co. (NYSE:BMY), the fund's Kurt von Emster told Ebb & Flow.

The pharma's tender offer for $885 million in cash ($9.75 per share) is an 84% premium to the biotech's close prior to the deal's announcement...